Markers of oxidative stress in obese men with and without hypertension.
OBJECTIVE
The aim of our study was to investigate if the 24-hour excretion of the urinary markers for oxidative stress to DNA and RNA, measured as 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydro-guanosine (8-oxoGuo), respectively, were increased in obese individuals with or without hypertension compared to lean controls.


METHODS
A total of 63 obese hypertensive men (obeseHT), 40 obese normotensive men (obeseNT) and 27 lean normotensive men (leanNT) were included in the study. Body mass index (BMI) was between 20.0 and 24.9 kg/m2in leanNT participants and ≥30 kg/m2in obese participants. Hypertension was defined as a mean 24-hour systolic ambulatory blood pressure (AMBP) ≥ 130 mmHg or a mean 24-hour diastolic AMBP ≥80 mmHg and normotension as mean 24-hour AMBP <130/80 mmHg. Twenty-four hour urinary 8-oxoGuo and 8-oxodG excretion (nmol/24 h) were measured by a validated liquid chromatography-tandem mass spectrometry method (UPLC-MS/MS).


RESULTS
Urinary 8-oxoGuo excretion was (median and [interquartile range]) 30.8 [27.8-32.2] nmol/24 h in leanNT, 36.8 [31.3-40.2] nmol/24 h in obeseNT and 40.6 [31.7-48.5] nmol/24 h in obeseHT. The difference was statistically significant (p = .002) and post hoc tests showed a significant difference between leanNT and obeseHT (p = .001) as well as obeseNT (p = .002), whereas the two obese groups did not differ (p = .6). No statistically significant differences in 8-oxodG concentrations were observed between the three groups (p = .3).


CONCLUSIONS
The measurement of urinary excretion of 8-oxoGuo suggests that obesity in men, but not hypertension, is associated with increased oxidative damage to RNA.
a Department of Clinical Pharmacology , Bispebjerg and Frederiksberg Hospital , Copenhagen , Denmark.|b Faculty of Health and Medical Sciences , University of Copenhagen , Copenhagen , Denmark.
Vanja
V
Cejvanovic
c Department of Medicine , Hvidovre Hospital Glostrup , Copenhagen , Denmark.|d Department of Clinical Physiology, Nuclear Medicine and PET, Glostrup section , Rigshospitalet , Copenhagen , Denmark.
Camilla
C
Asferg
a Department of Clinical Pharmacology , Bispebjerg and Frederiksberg Hospital , Copenhagen , Denmark.
Laura Kofoed
LK
Kjær
d Department of Clinical Physiology, Nuclear Medicine and PET, Glostrup section , Rigshospitalet , Copenhagen , Denmark.
Ulrik B
UB
Andersen
b Faculty of Health and Medical Sciences , University of Copenhagen , Copenhagen , Denmark.|e Research Centre for Prevention and Health , the Capital Region of Denmark, Copenhagen , Denmark.|f Department of Clinical Experimental Research , Rigshospitalet and Glostrup Hospital , Copenhagen , Denmark.
Allan
A
Linneberg
g Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health , Aarhus University , Aarhus , Denmark.|h Department of Endocrinology and Internal Medicine , Aarhus University Hospital , Aarhus , Denmark.
Jan
J
Frystyk
a Department of Clinical Pharmacology , Bispebjerg and Frederiksberg Hospital , Copenhagen , Denmark.
Trine
T
Henriksen
g Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health , Aarhus University , Aarhus , Denmark.|h Department of Endocrinology and Internal Medicine , Aarhus University Hospital , Aarhus , Denmark.
Allan
A
Flyvbjerg
i Department for Congenital Disorders , Statens Serum Institut , Copenhagen , Denmark.|j Department of Biomedical Sciences , University of Copenhagen , Copenhagen , Denmark.
Michael
M
Christiansen
a Department of Clinical Pharmacology , Bispebjerg and Frederiksberg Hospital , Copenhagen , Denmark.
Allan
A
Weimann
b Faculty of Health and Medical Sciences , University of Copenhagen , Copenhagen , Denmark.|c Department of Medicine , Hvidovre Hospital Glostrup , Copenhagen , Denmark.
Jørgen
J
Jeppesen
a Department of Clinical Pharmacology , Bispebjerg and Frederiksberg Hospital , Copenhagen , Denmark.|b Faculty of Health and Medical Sciences , University of Copenhagen , Copenhagen , Denmark.
Henrik Enghusen
HE
Poulsen
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D015415:Biomarkers / Q000652:urine; D001794:Blood Pressure; D018660:Blood Pressure Monitoring, Ambulatory; D015992:Body Mass Index; D016022:Case-Control Studies; D002853:Chromatography, Liquid / Q000592:standards; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000652:urine; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology / Q000652:urine*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000503:physiopathology / Q000652:urine*; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D012313:RNA / Q000737:chemistry* / Q000378:metabolism; D053719:Tandem Mass Spectrometry / Q000592:standards
D015415:Biomarkers; D012313:RNA; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine
8-oxo-7,8-dihydro-2'-deoxyguanosine; 8-oxo-7,8-dihydroguanosine; hypertension; obesity; oxidative stress; type 2 diabetes mellitus